Benralizumab, a medication licensed to treat severe eosinophilic asthma, was investigated as a possible therapy for eosinophilic gastritis. Benralizumab injections or placebo injections were given to 26 individuals with active eosinophilic gastritis in a limited phase 2 experiment. The primary outcome was histological remission, which was defined as a reduction in the number of stomach eosinophils below 30 per high-power field. After 12 weeks, 77% of patients on benralizumab achieved histological remission compared to just 8% of patients on placebo, demonstrating that benralizumab is effective at lowering gastric eosinophil levels. However, while benralizumab lowered eosinophil counts and other inflammatory markers, it had no effect on endoscopic scores, patient-reported outcomes, or structural alterations. Furthermore, benralizumab caused negative effects in some patients.

To know more: About the original article click here.